冠科生物,Crown Bioscience ,
中美冠科生物技術有限公司成立于2006年,是一家出色的新藥研發公司。在其專注的腫瘤和代謝疾病領域,冠科為生物科技和藥業合作伙伴提供最先進的轉化醫學研究平臺和高效的新藥研發解決方案。冠科獨有的HuPrime?, HuKemia?, HuBase?,HuTrialTM, HuSignatureTM 和HuMark?技術平臺提供特有的先導化合物優化和轉化醫學研究策略,獲得更優秀的臨床候選化合物。總部設在美國加利福利亞州圣塔克拉拉市(Santa Clara,California),在美國北卡羅來納州、英國中部、中國北京市和江蘇省太倉市均設有含動物房的生物醫藥研發中心。并在美國波士頓、普林斯頓、RTP、菲尼克斯、英國諾丁漢和意大利米蘭及中國上海設有辦事處
Founded in 2006, Crown Bioscience is a premier drug discovery company providing cutting-edge translational platforms and cost effective drug discovery solutions for its biotech and pharmaceutical partners in dedicated therapeutic areas: Oncology and Metabolic Disease. Our proprietary HuPrime?, HuKemia?, HuBase?, HuTrial?, HuSignature?, HuBank ?, HuTissue?, and HuMark? platforms enable unique lead optimization and translational strategies to deliver superior drug candidates. Headquartered in Santa Clara California, Crown Bioscience has global operations in China (Beijing and Jiangsu Taicang), the USA (NC), UK (Nottingham), and also with business offices in the Santa Clara, Boston, Princeton, RTP, Indianapolis, Phoenix, Milan and Shanghai.